

**Supplementary Table 1.** Summary of the studies included in the meta-analysis

Study author (year)	Sample size	Age (mean, range, or standard deviation)/ Sex (male:female)	Study design	Comparison	Outcome measure analyzed
Bachert (2016) [12]	60	Dupilumab group: 47.4 (9.8) years/18:12 Placebo 49.3 (9.1) years/16:14	Randomized controlled	Dupilumab group (16 weeks ) vs. Placebo group	Clinical symptomatic markers
Bachert (2019) [9]	276	LIBERTY NP SINUS-24 (24 weeks treatment) Dupilumab group: 52 (39–61) years/88:55 Placebo: 50 (41–60) years/70:63	Randomized controlled	Dupilumab group (24 weeks ) vs. Placebo group	Clinical symptomatic markers
	298	LIBERTY NP SINUS-52 (52 weeks treatment) Dupilumab group: 53 (42–63) years/87:58 Placebo: 53 (44–61) years/95:58		Dupilumab group (52 weeks ) vs. Placebo group	
Dharmarajan (2022) [14]	108	52.39±15.81 years/NA	Cohort study	LIBERTY NP SINUS-24 or LIBERTY NP SINUS-52	Clinical symptomatic markers
Bertlich (2022) [13]	75	NA/49:26	Cohort study	LIBERTY NP SINUS-52	Clinical symptomatic markers
Haxel (2022) [16]	49		Cohort study		Clinical symptomatic markers
Miglani (2023) [15]	295	52.0 (42–63) years/184:111	Cohort study	Dupilumab group (24 weeks)/ Dupilumab group (52 weeks) vs. ESS group	Clinical symptomatic markers
Torretta (2022) [17]	80	51.58 (23–78)/47:33	Observational study		Clinical symptomatic markers
Matsuyama (2023) [18]	10	60.1±9.77:3	Case series		Clinical symptomatic markers

NA, not available; ESS, endoscopic sinus surgery